Reza Fathi
Chief Tech/Sci/R&D Officer at REDHILL BIOPHARMA LTD.
Net worth: 74 913 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dror Ben-Asher | M | 59 | 15 years | |
| kristin Comer | F | - | - | |
| Eric Emile Swenden | M | 80 | 14 years | |
| David Wasserman | M | - | 7 years | |
| Ofer Tsimchi | M | 64 | 13 years | |
| Rick Scruggs | M | 64 | 8 years | |
| Adi Frish | M | 54 | 14 years | |
| Alla Felder | F | 50 | 5 years | |
| Kenneth Reed | M | 70 | 15 years | |
| Shmuel Cabilly | M | 74 | 14 years | |
| Ira N. Kalfus | M | 63 | - | |
| Gilead Raday | M | 49 | 14 years | |
| Terry F. Plasse | M | - | - | |
| Razi Ingber | M | - | 1 years | |
| Mark L. Levitt | M | - | 7 years | |
| Michelle Snelling | F | - | 5 years | |
| Rob Jackson | M | - | 5 years | |
| Alexandra Okmian | F | - | - | |
| Patricia Anderson | F | - | 7 years | |
| Dennis Selkoe | M | 80 |
Harvard Medical School
| 24 years |
| Shani Maurice | F | - | - | |
| Nezam Afdhal | M | 67 |
Harvard Medical School
| 24 years |
| Guy Goldberg | M | 48 | 12 years | |
| Barry S. Fogel | M | - |
Harvard Medical School
| 25 years |
| Thomas F. Deuel | M | 89 |
Harvard Medical School
| 26 years |
| Spyridon Artavanis-Tsakonas | M | 77 |
Harvard Medical School
| 25 years |
| Ori Shilo | M | 58 | - | |
| June Almenoff | M | 67 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Murray Goldberg | M | 79 |
PharmaGenics, Inc.
 PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | 4 years |
| Peter G. Tombros | M | 81 |
VivoQuest, Inc.
 VivoQuest, Inc. BiotechnologyHealth Technology VivoQuest, Inc. is engaged into the discovery and development of prescription drugs based on natural compounds derived small molecules. The in-house discovery research program in chemistry and biology aims at establishing and screening unique libraries of natural product-like compounds. VivoQuest's initial therapeutic area is the anti-viral field, including HIV and hepatitis C. VivoQuest is headquartered in Valley Cottage, NY. | 4 years |
| Dan Suesskind | M | 80 | - | |
| BILL Kessler | M | 57 | 4 years | |
| Ben Martie | M | - | - | |
| Danielle Abramson | M | - | - | |
| Nurit Benjamini | F | 57 | - | |
| Yung H. Chyung | M | 48 |
Harvard Medical School
| 3 years |
| Boris Bergus | M | 59 |
Harvard Medical School
| 3 years |
| Joan W. Miller | M | 65 |
Harvard Medical School
| 12 years |
| Annabel Chen-Tournoux | M | - |
Harvard Medical School
| 4 years |
| Uri Hananel Aharon | M | 43 | - | |
| Vamsi Mootha | M | - |
Harvard Medical School
| 3 years |
| Lishan Aklog | M | 58 |
Harvard Medical School
| 3 years |
| Aida Bibliowicz | F | - | - | |
| Stefan Heller | M | 58 |
Harvard Medical School
| 5 years |
| Valerie Graceffa | F | - | - | |
| Chun Kit Ho | M | 47 |
Harvard Medical School
| 3 years |
| Samuel H. Rudman | M | - | - | |
| Neil Graham | M | 65 | 3 years | |
| Leo Tsai | M | - |
Harvard Medical School
| 8 years |
| Vincent Ricchiuti | M | - |
Harvard Medical School
| 12 years |
| Einav Nagar-Brenner | F | 42 | 5 years | |
| Adam Lipson | M | 51 |
Harvard Medical School
| 3 years |
| Jae-Hong Park | M | 55 |
Harvard Medical School
| 3 years |
| Michael Brandt | M | - |
Harvard Medical School
| 2 years |
| Roni Mamluk | M | 57 |
Harvard Medical School
| 5 years |
| Stefan Feske | M | - |
Harvard Medical School
| - |
| Bruce A. Beutel | M | 60 |
PharmaGenics, Inc.
PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | 2 years |
| Ronald DePinho | M | 69 |
Harvard Medical School
| - |
| Stephen Oesterle | M | 73 |
Harvard Medical School
| 4 years |
| Ronald Bentsur | M | 58 | 3 years | |
| Qi Yuan Ma | M | 67 |
Harvard Medical School
| 5 years |
| Jeffrey Leiden | M | 68 |
Harvard Medical School
| 1 years |
| George M. Gould | M | 86 |
PharmaGenics, Inc.
PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | - |
| Peter Farrell | M | 81 |
Harvard Medical School
| 15 years |
| Jennifer Good | F | 59 | - | |
| Tim Anderson | M | - |
Harvard Medical School
| 2 years |
| Jonathan Burgin | M | 63 | 7 years | |
| Edward Benz | M | 78 |
Harvard Medical School
| 16 years |
| Giuseppe Cipriano | M | 67 | - | |
| James E. Muller | M | 81 |
Harvard Medical School
| 5 years |
| Brett Zbar | M | 51 |
Harvard Medical School
| 4 years |
| Gerald Fischbach | M | - |
Harvard Medical School
| 8 years |
| Dan Moriarty | M | - |
Harvard Medical School
| 1 years |
| Laurence Charney | M | 76 | - | |
| David Berry | M | 47 |
Harvard Medical School
| 6 years |
| Alicia Rotbard | F | 78 | 4 years | |
| Micha Ben-Chorin | M | 55 | 7 years | |
| Kenneth Zuerblis | M | 64 | 1 years | |
| Harris Rose | M | - |
Harvard Medical School
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 42 | 53.16% |
| United States | 37 | 46.84% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Reza Fathi
- Personal Network
